88,855 Shares in Harrow, Inc. $HROW Acquired by Lumbard & Kellner LLC

Lumbard & Kellner LLC bought a new position in Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 88,855 shares of the company’s stock, valued at approximately $4,281,000. Harrow accounts for approximately 1.6% of Lumbard & Kellner LLC’s investment portfolio, making the stock its 26th biggest position.

Other hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Harrow by 4.7% in the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after purchasing an additional 36,724 shares during the period. Marshall Wace LLP boosted its stake in Harrow by 31.5% during the second quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock valued at $17,251,000 after buying an additional 135,202 shares during the period. New York State Common Retirement Fund grew its position in Harrow by 1,944.7% during the third quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock worth $10,300,000 after buying an additional 203,333 shares in the last quarter. Bank of America Corp DE grew its position in Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after buying an additional 155,258 shares in the last quarter. Finally, Westside Investment Management Inc. increased its stake in Harrow by 4.1% in the 2nd quarter. Westside Investment Management Inc. now owns 181,056 shares of the company’s stock worth $5,529,000 after acquiring an additional 7,200 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $54.18 on Monday. The company has a quick ratio of 2.52, a current ratio of 2.72 and a debt-to-equity ratio of 5.21. The stock has a market cap of $2.01 billion, a PE ratio of -541.75 and a beta of 0.05. The company’s fifty day moving average is $48.53 and its 200 day moving average is $43.70. Harrow, Inc. has a 52 week low of $20.85 and a 52 week high of $54.85.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HROW. LADENBURG THALM/SH SH lifted their price target on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. HC Wainwright raised their target price on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $94.00 price objective on shares of Harrow in a research report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $71.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.